Acasti pharma stock price target
ACST Acasti Pharma, Inc. Class A Common Stock - NASDAQ.com Acasti Pharma, Inc. Class A Common Stock (ACST) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Acasti Pharma, Inc. Class A Common Stock (ACST) Analyst ... Mar 20, 2020 · Acasti Pharma, Inc. Class A Common Stock (ACST) Analyst Research. ACST Analyst Ratings. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00.
1 Oct 2019 Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) CSO & COO Pierre Lemieux tells Proactive the Québec-based company is 'marching to the
ACASTI PHARMA INC. : Target Price Consensus and Analysts ... ACASTI PHARMA INC. analysts consensus, targets, ratings and recommendations | TSX VENTURE EXCHANGE: ACST | TSX VENTURE EXCHANGE ACST:Venture Stock Quote - Acasti Pharma Inc - Bloomberg ... Stock analysis for Acasti Pharma Inc (ACST:Venture) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Acasti Pharma has price target cut at Echelon - Cantech Letter
Nov 09, 2019 · Acasti Pharma Inc. analyst estimates by MarketWatch. View ACST revenue estimates and earnings estimates, as well as analyst recommendations.
Buy, Sell or Hold: Acasti Pharma (ACST-X) — Stock ... Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock. Is Acasti Pharma worth watching? 7 stock analysts on Stockchase covered Acasti Pharma In the last year. It is a trending stock that is worth watching. What is Acasti Pharma stock price? On 2020-03-27, Acasti Pharma (ACST-X) stock closed at a Acasti Pharma, Inc. - ACST - Stock Price Today - Zacks View Acasti Pharma, Inc. ACST investment & stock information. Get the latest Acasti Pharma, Inc. ACST detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ACASTI PHARMA INC. : ACST Stock Price | MarketScreener Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in Acasti Pharma Inc (ACST-X) Quote - The Globe and Mail
ACST | Acasti Pharma Inc. Analyst Estimates | MarketWatch
Investor Relations :: Acasti Pharma Inc. (ACST)
Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the…
Mar 05, 2020 · The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not found any price forecast … Investor Relations :: Acasti Pharma Inc. (ACST) Stock Information. Company Overview. Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. Since its founding in 2008, Acasti Pharma has Acasti Pharma (Class A) - ACST - Stock Price & News | The ...
Acasti Pharma stock price target cut to $2 from $8 at B. Riley FBR MarketWatch. Monday, January 13, 2020. 02:32 PM ET. Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappoint MarketWatch. Thursday, July 18, 2019. 07:21 AM ET. Acasti Pharma started at outperform with $7 stock price target at Oppenheimer MarketWatch. More Acasti Pharma Inc. (ACST) Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the… ACASTI PHARMA INC (ACST.V) Stock Forum & Discussion ... Find the latest ACASTI PHARMA INC (ACST.V) stock discussion in Yahoo Finance's forum. Leland Gershell from Oppenheimer maintained a buy rating on Acasti Pharma with a price target of $7.00." LAVAL, Québec, April 01, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a Acasti Pharma Price Target | ACST Acasti Pharma Price Target. View 4,000+ financial data types. Browse View Full Chart Price Target Chart . View Price Target for ACST. Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. Start your free 7-Day Trial.